Trading on the NASDAQ Capital Market, iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions. Headquartered in Nashua, New Hampshire, with additional offices in Beavercreek, Ohio, their solutions enable healthcare professionals to serve patients better by identifying pathologies and pinpointing cancer earlier. The Company’s solutions aid in the early detection of the most prevalent cancers.

The Company received Food and Drug Administration (FDA) approval of their first breast-cancer detection product in 2002. Since then they placed more than 2,700 iCAD systems in healthcare practices around the globe. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems, and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Their systems are for the high, mid, and low volume mammography markets.

iCAD’s mammography CAD innovations include being the first system to offer a clear film-to-digital upgrade path, as well as the